08:00 , Dec 7, 2009 |  BioCentury  |  Finance

Ebb & Flow

The latest follow-on from Human Genome Sciences Inc. (NASDAQ:HGSI) will increase its cash to around $1.1 billion, more than enough to get Benlysta belimumab to market for systemic lupus erythematosus. Indeed, if all goes well,...
07:00 , Jul 13, 2009 |  BC Week In Review  |  Company News

Apoptos, Receptos deal

Receptos acquired cancer company Apoptos for an undisclosed sum. Apoptos develops small molecules that induce tumor cell apoptosis. Receptos is focused on G-protein coupled receptors (GPCR). Further terms were not disclosed. Apoptos Inc. , San...
07:00 , May 12, 2008 |  BC Week In Review  |  Company News

Apoptos board of directors update

Apoptos Inc. San Diego, Calif.   Business: Cancer   Appointed: Robert Nelsen, co-founder and managing director of Arch Venture Partners; and Mikael Dolsten, a partner at OrbiMed Advisors LLC  ...
01:56 , May 7, 2008 |  BC Extra  |  Financial News

Apoptos raises $14 million

Apoptos (San Diego, Calif.) raised about $14 million in the first of two tranches of a $28 million series A round led by existing investor Venrock. New investors OrbiMed Advisors and Advanced Technology Ventures joined...